| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥395M | ¥487M | -18.9% |
| Cost of Sales | ¥125M | ¥123M | +1.3% |
| Gross Profit | ¥271M | ¥364M | -25.6% |
| SG&A Expenses | ¥1.82B | ¥1.94B | -6.2% |
| Operating Income | ¥-1.55B | ¥-1.58B | +1.7% |
| Non-operating Income | ¥6M | ¥25M | -76.6% |
| Non-operating Expenses | ¥44M | ¥26M | +70.4% |
| Ordinary Income | ¥-1.59B | ¥-1.58B | -0.7% |
| Profit Before Tax | ¥-1.60B | ¥-1.58B | -0.9% |
| Income Tax Expense | ¥1M | ¥4M | -66.9% |
| Net Income | ¥-1.60B | ¥-1.59B | -0.7% |
| Net Income Attributable to Owners | ¥-1.60B | ¥-1.59B | -0.8% |
| Total Comprehensive Income | ¥-1.62B | ¥-1.59B | -2.1% |
| Interest Expense | ¥3M | ¥2M | +29.8% |
| Basic EPS | ¥-83.76 | ¥-90.52 | +7.5% |
| Dividend Per Share | ¥0.00 | ¥0.00 | - |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥1.48B | ¥2.74B | ¥-1.25B |
| Cash and Deposits | ¥925M | ¥2.11B | ¥-1.18B |
| Accounts Receivable | ¥71M | ¥87M | ¥-16M |
| Inventories | ¥109M | ¥108M | +¥1M |
| Non-current Assets | ¥52M | ¥34M | +¥18M |
| Item | Value |
|---|---|
| Net Profit Margin | -405.1% |
| Gross Profit Margin | 68.5% |
| Current Ratio | 917.6% |
| Quick Ratio | 849.9% |
| Debt-to-Equity Ratio | 0.78x |
| Interest Coverage Ratio | -497.91x |
| Effective Tax Rate | -0.1% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | -18.8% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 19.15M shares |
| Treasury Stock | 11K shares |
| Average Shares Outstanding | 19.10M shares |
| Book Value Per Share | ¥45.14 |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥0.00 |
| Year-End Dividend | ¥0.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| DrugDiscovery | - | ¥-1.49B |
| DrugDiscoverySupport | ¥395M | ¥-64M |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥722M |
| Operating Income Forecast | ¥-2.13B |
| Ordinary Income Forecast | ¥-2.14B |
| Net Income Attributable to Owners Forecast | ¥-2.15B |
| Basic EPS Forecast | ¥-112.46 |
| Dividend Per Share Forecast | ¥0.00 |
| Total Assets | ¥1.53B | ¥2.77B | ¥-1.24B |
| Current Liabilities | ¥162M | ¥223M | ¥-61M |
| Accounts Payable | ¥2M | ¥2M | ¥0 |
| Non-current Liabilities | ¥510M | ¥74M | +¥436M |
| Long-term Loans | ¥8M | ¥8M | ¥0 |
| Total Liabilities | ¥671M | ¥297M | +¥374M |
| Total Equity | ¥864M | ¥2.48B | ¥-1.61B |
| Capital Stock | ¥15M | ¥2.45B | ¥-2.43B |
| Capital Surplus | ¥2.20B | ¥6.20B | ¥-4.00B |
| Retained Earnings | ¥-1.41B | ¥-6.25B | +¥4.84B |
| Treasury Stock | ¥-222,000 | ¥-222,000 | ¥0 |
| Owners' Equity | ¥864M | ¥2.48B | ¥-1.61B |
| Working Capital | ¥1.32B | - | - |